Reportlinker.com

Reportlinker.com

March 18, 2008 18:22 ET

High Growth Reported for The Cardiovascular Disorders Market Outlook to 2012

LONDON, UNITED KINGDOM--(Marketwire - March 18, 2008) -

Reportlinker.com announces that a new market research report related to the Cardiovascular diseases industry is available in its catalogue.

The Cardiovascular Disorders Market Outlook to 2012

The Cardiovascular Disorders Market Outlook to 2012

Business Intelligence for the Pharmaceutical Industry

Business Insights' portfolio of healthcare management reports are designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry. Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight

Some key findings from this report...

- Zetia, Diovan, Crestor and Lipitor were the strongest performing major products of 2006-07. Each of these brands is forecast to maintain patent protection over the short to medium-term.

- The cardiovascular portfolios of Novartis and AstraZeneca are best positioned for high levels of future growth. Conversely, it is forecast that current market leaders Pfizer, Merck and Sanofi-Aventis will struggle to preserve their market shares over the 2008-12 period.

- The cardiac therapy area is the only segment forecast to experience a decline in net sales during the forecast period. However, generic competition to Lipitor may also result in the Dyslipidemia market suffering a fall in sales over 2011-12.

- Thrombosis will be the major growth driver of the cardiovascular area throughout the short-term, whilst heart failure has the most favourable dynamics of any indication for rapid market growth.

- Heart failure and thrombosis represent the most active areas of current drug development. Increasing competition in these traditionally less competitive therapeutic areas is forecast to become a major trend over the period up to 2012.

The Cardiovascular Market Outlook to 2012

The cardiovascular therapeutic area has historically provided the largest single source of revenue for the pharmaceutical industry. The outlook for the market remains robust, driven by high patient populations and a widespread focus on preventative treatment. However, low growth rates in established indications will prevail due to the growing availability of effective generic medicines and an overall scarcity of innovative new drug launches. Major pharma companies are now primarily focusing efforts upon compliance and protection against the generic threats posed by line extensions and combination treatments. Changes in the competitive positions of leading companies will become inevitable as new revenue sources continue to decline and established portfolios under perform. The Cardiovascular Disorders Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across all major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the period 2007-12. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth.

Top five reasons to order your copy today

- Assess patient potential, treatment trends and sales patterns across major cardiovascular indications with this report's analysis of epidemiological studies, unmet medical need, and economic imperatives for stakeholders.

- Measure the market performance and strategic positioning of major pharmaceutical corporations with this report's evaluation of the franchises and market shares of AstraZeneca, BMS, Daiichi Sankyo, GSK, Merck, Novartis, Pfizer, Sanofi-Aventis and Servier.

- Discover the market dynamics of the cardiovascular area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.

- Compare the future prospects of key players and forecast sales of leading products across major indications to 2012 with this report's analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and trends in promotional spend for key brands.

- Identify the strategies that offer the greatest success potential within the future cardiovascular market and understand the challenges currently facing companies within this therapeutic area.

Key issues examined in this report...

- Cardiac therapies. Heart failure treatments have become a focal point for cardiovascular drug developments. However, doubts remain over whether the marginal benefits offered by such medicines will be sufficient to generate and sustain high levels of revenue.

- Combination drugs. Although combination drugs failed to accrue strong sales growth in 2007, the growing acceptance of combination dyslipidemic therapies amongst payors and physicians will favour Merck's Vytorin/Inegy and Novartis' newly launched combination product Exforge (amlodipine/losartan)

- Empty pipelines. Currently marketed portfolios have taken on greater importance in light of weak late stage pipelines among players such as Merck, BMS and AstraZeneca. This lack of new revenue sources is forecast to depress future growth in the cardiovascular market.

- Market leaders. Few leading companies are expected to retain their presence in the cardiovascular market, with some major players set to experience drastic declines in revenue over the forecast period.

Your questions answered...

- Which indications will experience the greatest growth in the global cardiovascular market over the period 2007-12?

- How will generic competition influence the future of branded products and which defensive strategies provide the most effective protection?

- How have recent major product launches performed?

- What is the forecast market size and growth rate over the period 2007-2012 across the major cardiovascular indications?

- Which pipeline products offer the highest growth potential?

- What will be the competitive landscape of hypertension, thrombosis, dyslipidemia and arrhythmia in 2012?

Table of Contents

The Cardiovascular Disorders Market Outlook to 2012

Executive Summary 14

Patient potential 14

Global market analysis 15

Pipeline analysis 16

Competitive landscape 17

Chapter 1 Epidemiology of Cardiovascular disorders 20

Summary 20

Introduction 21

Cardiovascular Risk Factors 22

Hypertension 25

Overview 25

Diagnosis, treatment and management 26

Epidemiology 28

Forecast epidemiology 30

Dyslipidemia 31

Overview 31

Diagnosis, treatment and management 33

Epidemiology 35

Forecast epidemiology 36

Diabetes 37

Overview 37

Diagnosis, treatment and management 38

Epidemiology 40

Forecast epidemiology 41

Cardiovascular disease 42

Overview 42

Epidemiology 44

Acute thrombotic events 45

Acute coronary syndromes 45

Venous thromboembolism 48

Stroke 50

Cardiovascular procedures 53

Chapter 2 Global market analysis 58

Summary 58

Introduction 59

Market analysis by country 59

Licensing trends 60

Market analysis by drug class 62

Leading brands dynamics 64

Key events in the cardiovascular market 66

Use of ACE inhibitors by pregnant women linked to associated birth defects risks 66

Arrival of generic competition to key brands 67

Positive clinical trials further boost sales generation for major brands Diovan and Lipitor 67

Anti-hypertensives 68

Market analysis by drug class 68

Leading brands in the Anti-hypertensives market 70

ACE Inhibitors (ACEIs) 72

Market dynamics 74

Key brands analysis 75

Beta Blockers 80

Market dynamics 82

Diuretics 83

Market dynamics 85

Key brands analysis 85

Calcium Channel Blockers (CCBs) 86

Market dynamics 88

Key brands analysis 89

Angiotensin Receptor Blockers (ARBs) 90

Market dynamics 93

Key brands analysis 94

Sales forecasts to 2012 for Anti Hypertensives 100

Anti-dyslipidemics 102

Market analysis by drug class 102

Leading brands in the Anti-dyslipidemics market 105

Market analysis by drug class 106

Statins 106

Fibrates 113

Non-statin products 113

Other anti-dyslipidemics 115

Sales forecasts to 2012 for Anti-dyslipidemics 115

Anti-Thrombotics 116

Market analysis by drug class 116

Leading brand dynamics 119

Anti-platelets 121

Market dynamics 124

Key brands analysis 125

Heparins 128

Market dynamics 130

Key brands analysis 130

Vit K antagonists 134

Fibrinolytics 136

Sales forecasts to 2012 for Anti thrombotics 137

Cardiac Therapies 138

Market analysis by drug class 138

Leading brands of Cardiac Therapies 142

Other cardiac therapies 142

Nitrites and nitrates 144

Leading-brand dynamics 144

Anti-arrhythmics 145

Sales forecasts to 2012 for Cardiac Therapies 2007-12 146

Total CVD market sales forecasts to 2012 147

Chapter 3 Pipeline analysis 150

Summary 150

Introduction 151

Key trends in cardiovascular R&D 151

Combination drugs 152

New class of drugs 153

New mechanism of action 153

New drug delivery formulations 153

The pipeline for cardiovascular disorders 154

Leading drugs in development 156

Profiles of key pipeline products 157

Phase II compounds 157

ARC 1779 157

KB 2115 158

Phase III compounds 160

Cleviprex (clevidipine) 160

Stedicor (azimilide) 162

BAY-597939 (rivaroxaban) 163

Drugs pending approval 165

Thelin (sitaxsentan) 165

Simcor (niacin and simvastatin) 167

Recently marketed drugs 169

Azor (amlodipine/olmesartan) 169

Tekturna/Rasilez (aliskiren) 171

Exforge (amlodipine/valsartan) 173

Ranexa (ranolazine) 174

Chapter 4 Competitive landscape 178

Summary 178

Company market shares 179

Pfizer 183

Overview 183

Sales focus by drug class 183

Marketed product portfolio 184

R&D pipeline analysis 185

Strategic and growth analysis 186

Drivers of growth 186

Resistors of growth 186

Merck 187

Overview 187

Sales focus by drug class 187

Marketed product portfolio 188

R&D pipeline analysis 189

Strategic and growth analysis 190

Drivers of growth 190

Resistors of growth 190

Novartis 191

Overview 191

Sales focus by drug class 191

Marketed product portfolio 192

R&D compounds 193

Strategic and growth analysis 194

Drivers of growth 194

Resistors of growth 194

Sanofi Aventis 195

Overview 195

Sales focus by drug class 195

Marketed product portfolio 196

R&D pipeline analysis 197

Strategic and growth analysis 198

Drivers of growth 198

Resistors of growth 198

AstraZeneca 199

Overview 199

Sales focus by drug class 199

Marketed product portfolio 200

R&D pipeline analysis 201

Strategic and growth analysis 201

Drivers of growth 201

Resistors of growth 202

Bristol-Myers Squibb 203

Overview 203

Sales focus by drug class 203

Marketed product portfolio 204

R&D pipeline analysis 205

Strategic and growth analysis 205

Drivers of growth 205

Resistors of growth 206

Daiichi Sankyo 207

Overview 207

Sales focus by drug class 207

Marketed product portfolio 208

R&D pipeline analysis 209

Strategic and growth analysis 210

Drivers of growth 210

Resistors of growth 210

Servier 211

Overview 211

Sales focus by drug class 211

Marketed product portfolio 212

R&D pipeline analysis 213

Strategic and growth analysis 213

Drivers of growth 213

Resistors of growth 213

Glaxo SmithKline 214

Overview 214

Sales focus by drug class 214

Marketed product portfolio 215

R&D pipeline analysis 216

Strategic and growth analysis 217

Drivers of growth 217

Resistors of growth 217

Chapter 5 Appendix 220

ATC codes used in analysis 220

Licensing status as per IMS Health 220

Original brand 220

Other brand 221

Licensed brand 221

Not-coded product 221

Unbranded/ generic product 221

Diagnosis profile analysis 222

Index 223

List of Figures

Figure 1.1: Relationship between Cardiovascular Risk Factors and Diseases 23

Figure 1.2: Typical treatment patterns in the treatment of hypertension 28

Figure 1.3: Typical treatment patterns in the treatment of dyslipidemia 34

Figure 1.4: Typical treatment patterns in the treatment of diabetes 39

Figure 1.5: Typical treatment patterns in the treatment of acute thrombotic events 52

Figure 2.6: Global cardiovascular market share by geography, 2007 60

Figure 2.7: Sales of types of cardiovascular brands, 2006-07 61

Figure 2.8: Competitive dynamics of the global CVD market by drug class, 2007 63

Figure 2.9: Forecast dynamics of the leading 10 cardiovascular brands, 2006-07 66

Figure 2.10: Competitive dynamics in the global anti-hypertensives market by drug class, 2006-07 69

Figure 2.11: Market movement for anti-hypertensive brands, 2006 71

Figure 2.12: Diagnosis profile of ACE inhibitor sales, 2006 73

Figure 2.13: Diagnosis profile of Beta Blockers, 2006 81

Figure 2.14: Diagnosis profile of Calcium channel blockers, 2006 87

Figure 2.15: Diagnosis profile of ARBs, 2006 92

Figure 2.16: Diagnosis profile of Anti-dyslipidemics, 2006 104

Figure 2.17: Competitive dynamics in the global anti-thrombotics market by class, 2006-07 119

Figure 2.18: Market movement for anti-thrombotic brands, 2006 121

Figure 2.19: Diagnosis profile of anti-platelets, 2006 123

Figure 2.20: Diagnosis profile of Heparins, 2006 129

Figure 2.21: Diagnosis profile of cardiac therapies, 2006 140

Figure 2.22: Competitive dynamics in the global cardiac therapies market by class, 2006-07 141

Figure 3.23: Prevailing R&D approaches for cardiovascular diseases, 2006 152

Figure 3.24: The CVD pipeline by indication and stage of development, 2006 155

Figure 3.25: Leading recently launched and late-stage cardiovascular products, 2007 156

Figure 4.26: Competitive dynamics of the leading players in the global cardiovascular market, 2007 182

Figure 4.27: Pfizer's franchise sales by drug class, 2006 183

Figure 4.28: Merck's franchise sales by drug class, 2006 187

Figure 4.29: Novartis' franchise sales by drug class, 2006 191

Figure 4.30: Sanofi Aventis' franchise sales by drug class, 2006 195

Figure 4.31: AstraZeneca's franchise sales by drug class, 2006 199

Figure 4.32: BMS' franchise sales by drug class, 2006 203

Figure 4.33: Daiichi's franchise sales by drug class, 2006 207

Figure 4.34: Servier's franchise sales by drug class, 2006 211

Figure 4.35: GSK's franchise sales by drug class, 2006 214

List of Tables

Table 1.1: Estimated prevalence of CVD across the seven major pharmaceutical markets, 2006 24

Table 1.2: Proposed revision definition of hypertension, 2005 26

Table 1.3: Estimated prevalence of hypertension in across seven major markets, 2006 29

Table 1.4: Forecast epidemiology of hypertension across the seven major markets, 2006-12 30

Table 1.5: Clinical guidelines for adult patients at borderline and high risk of cardiovascular disease by serum levels of lipids 33

Table 1.6: Estimated prevalence of dyslipidemia across seven major markets, 2006 35

Table 1.7: Forecast epidemiology of dyslipidemia across the seven major markets, 2006-12 36

Table 1.8: Various pharmacological therapies for the treatment and management of diabetes 39

Table 1.9: Estimated prevalence of diabetes in the seven major markets, 2006 40

Table 1.10: Forecast epidemiology of diabetes across the seven major markets, 2006-12 41

Table 1.11: Estimated prevalence of major cardiovascular diseases in the seven major markets, 2006 44

Table 1.12: Estimated incidence of ACS in the seven major markets, 2006 47

Table 1.13: Estimated incidence of VTE in the seven major markets, 2006 49

Table 1.14: Prevalence of stroke in the seven major markets, 2006 51

Table 1.15: Estimated incidence of cardiovascular procedures in the seven major markets, 2006 54

Table 2.16: Breakdown of the global CVD market by drug class, 2003-07 62

Table 2.17: Leading brands in the global cardiovascular market, 2006-07 64

Table 2.18: Breakdown of the global anti-hypertensive market by drug class, 2003-07 68

Table 2.19: Leading anti-hypertensive brands, 2006-07 70

Table 2.20: Leading ACE inhibitor brands, 2006-07 74

Table 2.21: Leading Beta blocker brands, 2006-07 82

Table 2.22: Leading diuretics brands, 2006-07 85

Table 2.23: Leading CCBs brands in the global CVD market, 2006-07 88

Table 2.24: Leading ARBs brands in the global CVD market, 2006-07 93

Table 2.25: Anti-hypertensives sales forecast for ARBs, Beta-blockers & CCBs, 2007-12 100

Table 2.26: Anti-hypertensives sales forecast for ACE inhibitors, Diuretics & Pipeline products, 2007-12 101

Table 2.27: Breakdown of the global anti-dyslipidemic market by drug class, 2003-07 103

Table 2.28: Leading anti-dyslipidemia products in the global CVD market, 2006-07 105

Table 2.29: Anti-dyslipidemics sales forecasts, 2007-12 116

Table 2.30: Breakdown of the global anti-thrombotics market by drug class, 2003-07 117

Table 2.31: Leading anti-thrombotics products in the global CVD market, 2006-07 120

Table 2.32: Leading anti-platelet brands in the global CVD market, 2006-07 124

Table 2.33: Leading heparin brands in the global CVD market, 2006-07 130

Table 2.34: Anti-thrombotics sales forecasts, 2007-12 137

Table 2.35: Breakdown of the global anti-thrombotics market by drug class, 2003-07 139

Table 2.36: Leading cardiac therapy products in the global CVD market, 2006-07 142

Table 2.37: Cardiac therapies' sales forecasts, 2007-12 146

Table 2.38: Cardiovacular market sales forecasts by drug class, 2006-12 ($m) 147

Table 4.39: Leading players in the global cardiovascular disorders market, 2006-07 179

Table 4.40: Pfizer's CVD product portfolio, 2005-06 184

Table 4.41: Pfizer's cardiovascular product pipeline, 2006 185

Table 4.42: Merck's CVD product portfolio, 2005-06 188

Table 4.43: Merck's cardiovascular R&D product pipeline, 2006 189

Table 4.44: Novartis' CVD product portfolio, 2005-06 192

Table 4.45: Novartis' cardiovascular R&D product pipeline, 2006 193

Table 4.46: Sanofi Aventis' CVD product portfolio, 2005-06 196

Table 4.47: Sanofi Aventis' cardiovascular R&D product pipeline, 2006 197

Table 4.48: AstraZeneca's CVD product portfolio, 2005-06 200

Table 4.49: AstraZeneca's cardiovascular R&D product pipeline, 2006 201

Table 4.50: BMS's CVD product portfolio, 2005-06 204

Table 4.51: BMS' cardiovascular R&D product pipeline, 2006 205

Table 4.52: Daiichi's CVD product portfolio, 2005-06 208

Table 4.53: Daichii's cardiovascular R&D product pipeline, 2006 209

Table 4.54: Servier's CVD product portfolio, 2005-06 212

Table 4.55: GSK's CVD product portfolio, 2005-06 215

Table 4.56: GSK's cardiovascular R&D product pipeline, 2006 216

To order this report:

The Cardiovascular Disorders Market Outlook to 2012

More market research reports here

Contact Information